Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease.
Crohn's disease and ulcerative colitis have a feature in common (i.e., chronic inflammation). Their clinical management requires repeated assessments; endoscopy with histological examination remains the gold standard for detecting and quantifying intestinal inflammation. An ideal marker should be quick and easy to obtain noninvasively, and should be inexpensive and reproducible. Several laboratory tests have been studied but, to date, a disease marker is not yet available. A combination of signs and symptoms, laboratory findings and imaging techniques is consequently still needed for assessing disease activity and prognosis. In recent years, research has drawn attention to fecal markers owing to their specificity for intestinal inflammation, ease of sample collection, availability of commercial immunoassays and convenience. Biological markers have been used to assess inflammatory bowel disease patients for the purposes of their clinical management, monitoring disease activity, predicting relapses, assessing prognosis and monitoring response to treatment.
Caccaro
Roberta
R
Department of Surgical and Gastroenterological Sciences, University of Padua, Via Giustiniani 2, 35127 Padova, Italy.
D'Incá
Renata
R
Sturniolo
Giacomo Carlo
GC
D015415:Biomarkers / Q000032:analysis*; D003937:Diagnosis, Differential; D005243:Feces / Q000737:chemistry; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000175:diagnosis* / Q000378:metabolism; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000175:diagnosis* / Q000378:metabolism; D007781:Lactoferrin / Q000032:analysis*; D039841:Leukocyte L1 Antigen Complex / Q000032:analysis*; D011237:Predictive Value of Tests; D011379:Prognosis
D015415:Biomarkers; D039841:Leukocyte L1 Antigen Complex; D007781:Lactoferrin